• Login
    View Item 
    •   Carroll Scholars Home
    • Carroll College Student Undergraduate Research Festival
    • Carroll College Student Undergraduate Research Festival 2022
    • View Item
    •   Carroll Scholars Home
    • Carroll College Student Undergraduate Research Festival
    • Carroll College Student Undergraduate Research Festival 2022
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Radioligand Therapy and Targeted Antigen Therapy in Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review

    Thumbnail
    View/Open
    Poster Presentation (379.3Kb)
    Powerpoint Poster (1.014Mb)
    Author
    Jensen, Lucas
    Advisor
    Schafer, Gerald
    Date of Issue
    2022
    Metadata
    Show full item record
    URI
    https://scholars.carroll.edu/handle/20.500.12647/10511
    Title
    Radioligand Therapy and Targeted Antigen Therapy in Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review
    Type
    Presentation
    Abstract
    Objective: To review current literature about the treatment of metastatic castration-resistant prostate cancer (mCRPC) by comparing radioligand therapy (RLT) and targeted antigen therapy (TAT) to standard treatment options. Methods: Literature was gathered through PubMed and CINHAL to investigate the effectiveness of RLT with Lutetium-177 and TAT with Actinium-225 in treating this cancer. Results: The literature showed significant decrease in cancer volumes and an increase in overall survival with both treatments in patients with mCRPC. The findings indicate that TAT with Actinium-225 displayed a greater decrease in cancer volume and longer overall survival, compared to RLT with Lutetium-177. Conclusion: RLT and TAT have shown positive effects in treating patients with mCRPC compared to standard treatments like chemotherapy. More research is needed to be done to determine which treatment is more effective, Lutetium-177 or Actinium-225. Keywords: Radioligand therapy; targeted antigen therapy; metastatic castration-resistant prostate cancer; Lutetium-177; Actinium-225.
    Department
    Health Sciences
    Collections
    • Carroll College Student Undergraduate Research Festival 2022

    Browse

    All of Carroll ScholarsCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2022  DuraSpace
    DSpace Express is a service operated by 
    Atmire NV